ZLN005 Chemical Properties

Melting point:

257-258℃

Boiling point:

415.3±38.0 °C(Predicted)

Density 

1.102±0.06 g/cm3(Predicted)

storage temp. 

Sealed in dry,Store in freezer, under -20°C

solubility 

DMSO: soluble10mg/mL, clear

pka

11.52±0.10(Predicted)

form 

powder

color 

white to beige

Safety Information

Hazard Codes 

Xn

Risk Statements 

22-36

Safety Statements 

26

WGK Germany 

3

ZLN005 Usage And Synthesis

Description

Peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) is a tissue-specific and inducible transcriptional coactivator for several nuclear receptors and plays a key role in energy metabolism, hepatic gluconeogenesis, and cholesterol homoeostasis. ZLN005 is a small molecule that stimulates the expression of PGC-1α and downstream genes in skeletal muscle cells, improving glucose utilization and fatty acid oxidation at a concentration of 20 μM. Chronic administration of 15 mg/kg/day ZLN005 to diabetic db/db mice increased PGC-1α and downstream gene transcription in skeletal muscle, increasing fat oxidation and improving glucose tolerance, pyruvate tolerance, and insulin sensitivity.

Uses

ZLN005 increaces PGC-1α and downstream gene transcription in skeletal muscles and increases fat oxidation and improved the glucose tolerance, pyruvate tolerance, and insulin sensitivity of diabetic db/db mice.

Synthesis

The reaction was carried out in a magnetically stirred round-bottomed flask equipped with a condenser and placed in a temperature-controlled oil bath. O-phenylenediamine (2 mmol) was added to 4-tert-butylbenzyl alcohol (3 mmol) and the reaction mixture was stirred at 135 °C in an open (air) atmosphere. The reaction was monitored by TLC and after complete disappearance of the o-phenylenediamine or after the reaction had reached a predetermined time, the reaction mixture was cooled to room temperature. The crude product was purified by column chromatography on silica gel (100-200 mesh) to afford 2-(4-(tert-butyl)phenyl)-1H-benzo[d]imidazole. All products were structurally confirmed by nuclear magnetic resonance (NMR) and mass spectrometry (MS) data.

in vivo

References

[1] Advanced Synthesis and Catalysis, 2017, vol. 359, # 19, p. 3332 - 3340
[2] Tetrahedron Letters, 2014, vol. 55, # 48, p. 6520 - 6525
[3] Catalysis Letters, 2018, vol. 148, # 1, p. 30 - 40
[4] New Journal of Chemistry, 2018, vol. 42, # 8, p. 6449 - 6456

ZLN005(49671-76-3)Related Product Information

• ZLN-024 hydrochloride
• BLU 9931
• Esomeprazole magnesium
• Tariquidar
• Palbociclib
• IXABEPILONE
• PF-04929113
• 4-(6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl)-2-((1r,4r)-4-hydroxycyclohexylamino)benzamide
• L-4-THIAZOLYLALANINE
• Ilomastat
• AZD-1208
• Crenolanib
• Doxorubicin hydrochloride
• BAY 11-7082
• 6-CHLORO-2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-1-CARBOXAMIDE
• Saracatinib
• T0070907
• PD 98059